All lobbying filings

MARSHALL & POPP, LLC

Lobbying for JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES · Pharmaceuticals.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · California · House · Senate · $40,000.00 income · posted Jul 21, 2025

Official filing document

Bills named in this filing 4

HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 4121
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
HR 946
ORPHAN Cures Act

Lobbying activity 2

Budget/Appropriations

Issues related to budget reconciliation, including H.Con.Res. 14.

Health Issues

Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including H.R. 1, FY25 budget reconciliation, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R. 4121, FY26 Agriculture, FDA and Related Agencies Appropriations. H.R.946 - ORPHAN Cures Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.